Literature DB >> 12811544

Current chemotherapy of human African trypanosomiasis.

Roberto Docampo1, Silvia N J Moreno.   

Abstract

Human African trypanosomiasis is a fatal disease caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense that has re-emerged in recent years. However, very little progress has been made in the development of new drugs against this disease. Most drugs still in use were developed one or more decades ago, and are generally toxic and of limited effectiveness. The most recently introduced compound, eflornithine, is only useful against sleeping sickness caused by T. b. gambiense, and is prohibitively expensive for the African developing countries. We present here an overview of today's approved and clinically used drugs against this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12811544     DOI: 10.1007/s00436-002-0752-y

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  36 in total

Review 1.  Autophagy in protists.

Authors:  Michael Duszenko; Michael L Ginger; Ana Brennand; Melisa Gualdrón-López; María Isabel Colombo; Graham H Coombs; Isabelle Coppens; Bamini Jayabalasingham; Gordon Langsley; Solange Lisboa de Castro; Rubem Menna-Barreto; Jeremy C Mottram; Miguel Navarro; Daniel J Rigden; Patricia S Romano; Veronika Stoka; Boris Turk; Paul A M Michels
Journal:  Autophagy       Date:  2011-02-01       Impact factor: 16.016

2.  Characterization of farnesylated protein tyrosine phosphatase TcPRL-1 from Trypanosoma cruzi.

Authors:  Ileana C Cuevas; Peter Rohloff; Daniel O Sánchez; Roberto Docampo
Journal:  Eukaryot Cell       Date:  2005-09

3.  Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.

Authors:  Yuliya V Mishina; Sanjeev Krishna; Richard K Haynes; John C Meade
Journal:  Antimicrob Agents Chemother       Date:  2007-03-05       Impact factor: 5.191

Review 4.  Neuroparasitic infections: cestodes, trematodes, and protozoans.

Authors:  M D Walker; J R Zunt
Journal:  Semin Neurol       Date:  2005-09       Impact factor: 3.420

5.  Structural and Functional Highlights of Vacuolar Soluble Protein 1 from Pathogen Trypanosoma brucei brucei.

Authors:  Abhishek Jamwal; Adam R Round; Ludovic Bannwarth; Catherine Venien-Bryan; Hassan Belrhali; Manickam Yogavel; Amit Sharma
Journal:  J Biol Chem       Date:  2015-10-22       Impact factor: 5.157

6.  Activity of indenoisoquinolines against African trypanosomes.

Authors:  Rahul P Bakshi; Dongpei Sang; Andrew Morrell; Mark Cushman; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

7.  A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity.

Authors:  Elizabeth R Sharlow; Todd A Lyda; Heidi C Dodson; Gabriela Mustata; Meredith T Morris; Stephanie S Leimgruber; Kuo-Hsiung Lee; Yoshiki Kashiwada; David Close; John S Lazo; James C Morris
Journal:  PLoS Negl Trop Dis       Date:  2010-04-13

8.  Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.

Authors:  Robert H Barker; Hanlan Liu; Bradford Hirth; Cassandra A Celatka; Richard Fitzpatrick; Yibin Xiang; Erin K Willert; Margaret A Phillips; Marcel Kaiser; Cyrus J Bacchi; Aixa Rodriguez; Nigel Yarlett; Jeffrey D Klinger; Edmund Sybertz
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

Review 9.  Aquaglyceroporins: generalized metalloid channels.

Authors:  Rita Mukhopadhyay; Hiranmoy Bhattacharjee; Barry P Rosen
Journal:  Biochim Biophys Acta       Date:  2013-11-27

10.  Vinyl sulfones as antiparasitic agents and a structural basis for drug design.

Authors:  Iain D Kerr; Ji H Lee; Christopher J Farady; Rachael Marion; Mathias Rickert; Mohammed Sajid; Kailash C Pandey; Conor R Caffrey; Jennifer Legac; Elizabeth Hansell; James H McKerrow; Charles S Craik; Philip J Rosenthal; Linda S Brinen
Journal:  J Biol Chem       Date:  2009-07-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.